Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 171 | 35 | 136 |
| Samples | 86 | 20 | 66 |
| Peptides | 63 | 13 | 51 |
Function
PSMB9 · Proteasome 20S subunit beta 9
The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 1 (proteasome beta 6 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. [provided by RefSeq, Mar 2010].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 61 amino-acid changes on canonical ENST00000374859 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PSMB9 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PSMB9 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Endometrial Carcinoma | 2/42 5% | 3/612 0% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Colorectal Carcinoma | 1/143 1% | 12/3239 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 6/1592 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Melanoma | 3/210 1% | 3/1899 0% |
| Ovarian Carcinoma | 1/109 1% | 2/998 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| Gastric Carcinoma | 1/74 1% | 3/1809 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Other Solid Cancers | 1/94 1% | 2/1515 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Hepatocellular Carcinoma | 2/46 4% | 2/2210 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 4/2550 0% |
| Glioma | 1/52 2% | 2/2127 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 1/1390 0% |
| Pancreatic Carcinoma | 1/89 1% | 0/1611 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
| Breast Carcinoma | 0/144 0% | 1/3264 0% |
Mutation Distribution
Where PSMB9 is mutated · all tissues, split by cell line vs tissue
How many mutations in PSMB9 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 171 mutations in PSMB9
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|